Stocky turns companies like THC BioMed Intl Ltd. into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Avoid. THCBF scores 21/100 on Value Compounder metrics, signaling weak fundamentals with limited margin of safety. Leadership Alignment at 36.3/100 reflects misaligned incentives and governance concerns, while the Vulnerable profile—despite a 0/100 Vulnerability Index—suggests structural headwinds in cannabis retail where competitive intensity and regulatory uncertainty erode returns. Wait for material operational improvement before reconsidering.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for THC BioMed Intl Ltd.:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 20/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates THC BioMed Intl Ltd. (THCBF) at 20/100 — an Avoid — fundamentals or risks are too weak. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Avoid. THCBF scores 21/100 on Value Compounder metrics, signaling weak fundamentals with limited margin of safety. Leadership Alignment at 36.3/100 reflects misaligned incentives and governance concerns, while the Vulnerable profile—despite
THCBF's current Stocky Verdict is 20/100, placing it in the "Avoid" band. This composite combines a 21/100 Compounder score, 36/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for THC BioMed Intl Ltd. yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
THC BioMed Intl Ltd. scores 36/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
THC BioMed Intl Ltd.'s Vulnerability Profile scores 0/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to THC BioMed Intl Ltd..
Sign up free and unlock the full analysis on THCBF — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for THCBF in the app.
